Found: 9
Select item for more details and to access through your institution.
Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 961, doi. 10.1111/dom.14940
- By:
- Publication type:
- Article
Correction to: Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis.
- Published in:
- Clinical Drug Investigation, 2020, v. 40, n. 7, p. 665, doi. 10.1007/s40261-020-00929-z
- By:
- Publication type:
- Article
Effect of Dapagliflozin Versus Empagliflozin on Cardiovascular Death in Patients with Heart Failure Across the Spectrum of Ejection Fraction: Cost per Outcome Analysis.
- Published in:
- American Journal of Cardiovascular Drugs, 2023, v. 23, n. 3, p. 323, doi. 10.1007/s40256-023-00578-5
- By:
- Publication type:
- Article
Aspirin with Low-Dose Ticagrelor or with Low-Dose Rivaroxaban for Secondary Prevention: A Cost per Outcome Analysis.
- Published in:
- American Journal of Cardiovascular Drugs, 2022, v. 22, n. 6, p. 677, doi. 10.1007/s40256-022-00543-8
- By:
- Publication type:
- Article
Dapagliflozin Versus Sacubitril–Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus.
- Published in:
- American Journal of Cardiovascular Drugs, 2022, v. 22, n. 3, p. 325, doi. 10.1007/s40256-021-00506-5
- By:
- Publication type:
- Article
Dapagliflozin versus sacubitril-valsartan for heart failure with mildly reduced or preserved ejection fraction.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1357673
- By:
- Publication type:
- Article
Dapagliflozin versus empagliflozin in patients with chronic kidney disease.
- Published in:
- Frontiers in Pharmacology, 2023, v. 14, p. 01, doi. 10.3389/fphar.2023.1227199
- By:
- Publication type:
- Article
Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis.
- Published in:
- Obesity (19307381), 2023, v. 31, n. 6, p. 1510, doi. 10.1002/oby.23752
- By:
- Publication type:
- Article